| Literature DB >> 29891534 |
Marion Lenglet1,2,3, Florence Robriquet2,3, Klaus Schwarz4,5, Carme Camps6,7, Anne Couturier8, David Hoogewijs9, Alexandre Buffet10,11,12, Samantha J L Knight6,7, Sophie Gad1,13, Sophie Couvé1,13, Franck Chesnel8, Mathilde Pacault2,14, Pierre Lindenbaum3, Sylvie Job15, Solenne Dumont2, Thomas Besnard3,14, Marine Cornec3, Helene Dreau16, Melissa Pentony6,7, Erika Kvikstad6,7, Sophie Deveaux17,18,19,20, Nelly Burnichon10,11,12,18,19,21, Sophie Ferlicot17,22, Mathias Vilaine2, Jean-Michaël Mazzella10,11,12,18,19,21, Fabrice Airaud14, Céline Garrec14, Laurence Heidet23, Sabine Irtan24, Elpis Mantadakis25, Karim Bouchireb23, Klaus-Michael Debatin26, Richard Redon3, Stéphane Bezieau3,14, Brigitte Bressac-de Paillerets13,27, Bin Tean Teh28, François Girodon29,30,31, Maria-Luigia Randi32, Maria Caterina Putti33, Vincent Bours34, Richard Van Wijk35, Joachim R Göthert36, Antonis Kattamis37, Nicolas Janin38, Celeste Bento39, Jenny C Taylor6,7, Yannick Arlot-Bonnemains8, Stéphane Richard1,13,17,18,19,20, Anne-Paule Gimenez-Roqueplo10,11,12,18,19,21, Holger Cario26, Betty Gardie1,2,3,31.
Abstract
Chuvash polycythemia is an autosomal recessive form of erythrocytosis associated with a homozygous p.Arg200Trp mutation in the von Hippel-Lindau (VHL) gene. Since this discovery, additional VHL mutations have been identified in patients with congenital erythrocytosis, in a homozygous or compound-heterozygous state. VHL is a major tumor suppressor gene, mutations in which were first described in patients presenting with VHL disease, which is characterized by the development of highly vascularized tumors. Here, we identify a new VHL cryptic exon (termed E1') deep in intron 1 that is naturally expressed in many tissues. More importantly, we identify mutations in E1' in 7 families with erythrocytosis (1 homozygous case and 6 compound-heterozygous cases with a mutation in E1' in addition to a mutation in VHL coding sequences) and in 1 large family with typical VHL disease but without any alteration in the other VHL exons. In this study, we show that the mutations induced a dysregulation of VHL splicing with excessive retention of E1' and were associated with a downregulation of VHL protein expression. In addition, we demonstrate a pathogenic role for synonymous mutations in VHL exon 2 that altered splicing through E2-skipping in 5 families with erythrocytosis or VHL disease. In all the studied cases, the mutations differentially affected splicing, correlating with phenotype severity. This study demonstrates that cryptic exon retention and exon skipping are new VHL alterations and reveals a novel complex splicing regulation of the VHL gene. These findings open new avenues for diagnosis and research regarding the VHL-related hypoxia-signaling pathway.Entities:
Mesh:
Substances:
Year: 2018 PMID: 29891534 DOI: 10.1182/blood-2018-03-838235
Source DB: PubMed Journal: Blood ISSN: 0006-4971 Impact factor: 22.113